Patents matching “anti-”

US 9827310

Anti-ErbB3 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Nov 28, 2017 · Expires Nov 23, 2037

US 9822162

Anti-human papillomavirus 16 E6 T cell receptors

The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Nov 21, 2017 · Expires Nov 16, 2037

US 9803021

CD138-targeted interferon demonstrates potent apoptotic and anti-tumor activities

The Regents of the University of California · Granted Oct 31, 2017 · Expires Oct 26, 2037

US 9790281

Humanized anti-CD134 (OX40) antibodies and uses thereof

Biocerox Products B.V. · Granted Oct 17, 2017 · Expires Oct 12, 2037

US 9790273

Anti-HLA-B*27 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2017 · Expires Oct 12, 2037

US 9789184

Anti-EGFR antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Oct 17, 2017 · Expires Oct 12, 2037

US 9790285

Anti-CD38 antibodies

Takeda Pharmaceutical Company Limited · Granted Oct 17, 2017 · Expires Oct 12, 2037

US 9782428

Method for generation of broadly neutralizing anti-pathogen antibodies

Northwestern University · Granted Oct 10, 2017 · Expires Oct 5, 2037

US 9770414

Sustained release formulation of methotrexate as a disease-modifying antirheumatic drug (DMARD) and an anti-cancer agent

Pacira Pharmaceuticals, Inc. · Granted Sep 26, 2017 · Expires Sep 21, 2037

US 9765147

Anti-CSFR1 antibody and anti PD-1 antibody combination therapy for cancer

Five Prime Therapeutics, Inc. · Granted Sep 19, 2017 · Expires Sep 14, 2037

US 9751932

Anti-big-endothelin-1 (big-ET-1) antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Sep 5, 2017 · Expires Aug 31, 2037

US 9745376

Anti-ανβ6 antibodies

The Regents of the University of California · Granted Aug 29, 2017 · Expires Aug 24, 2037

US 9737477

Anti-aging dietary composition containing polysaccharides derived from ginseng and tuber fleeceflower root

INFINITUS (CHINA) COMPANY LTD. · Granted Aug 22, 2017 · Expires Aug 17, 2037

US 9732114

Compounds having anti-adhesive effects on cancer cells

The Board of Regents of the University of Texas System · Granted Aug 15, 2017 · Expires Aug 10, 2037

US 9725475

Arsenoplatin anti-cancer agents

Northwestern University · Granted Aug 8, 2017 · Expires Aug 3, 2037

US 9718881

Anti-Activin A antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Aug 1, 2017 · Expires Jul 27, 2037

US 9707262

Composition with anoxia-tolerant and anti-fatigue effects and use thereof

INFINITUS (CHINA) COMPANY LTD. · Granted Jul 18, 2017 · Expires Jul 13, 2037

US 9701758

Anti-CD19 scFv (FMC63) polypeptide

The Board of Regents of the University of Texas System · Granted Jul 11, 2017 · Expires Jul 6, 2037

US 9701740

Cell-penetrating anti-DNA antibodies and uses thereof inhibit DNA repair

THE UNITED STATES OF AMERICA REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS · Granted Jul 11, 2017 · Expires Jul 6, 2037

US 9695246

Anti-OX40 antibodies and methods of using the same

The Board of Regents of the University of Texas System · Granted Jul 4, 2017 · Expires Jun 29, 2037

US 9694071

Combination of anti-CD20 antibody and PI3 kinase selective inhibitor

TG Therapeutics, Inc. · Granted Jul 4, 2017 · Expires Jun 29, 2037

US 9688764

Methods of treating breast cancer by administering anti-human prolactin receptor (PRLR) antibodies

REGENERON PHARMACEUTICALS, INC. · Granted Jun 27, 2017 · Expires Jun 22, 2037

US 9688748

Anti-jagged 1/jagged 2 cross-reactive antibodies, activatable anti-jagged antibodies and methods of use thereof

CytomX Therapeutics, Inc. · Granted Jun 27, 2017 · Expires Jun 22, 2037

US 9676869

Conjugated anti-CD38 antibodies

Takeda Pharmaceutical Company Limited · Granted Jun 13, 2017 · Expires Jun 8, 2037